Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: Sitravatinib + Nivolumab vs Docetaxel in Advanced Non-Squamous NSCLC After Platinum and Checkpoint Inhibitor Therapy
2024-516598-60-00Phase 3Completed
- Sponsor
- Mirati Therapeutics
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of sitravatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoint: Overall Survival. Started Dec 2020; status: completed.
02
Drugs
sitravatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-516598-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516598-60-00.